Navigation Links
Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
Date:9/23/2009

Berlin, Germany: Researchers have made significant advances in the treatment of metastatic malignant melanoma one of the most difficult cancers to treat successfully once it has started to spread according to a study to be presented at Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin on Thursday.

In the phase I extension study, researchers have seen rapid and dramatic shrinking of metastatic tumours in patients treated with a new compound that blocks the activity of the cancer-causing mutation of the BRAF gene, which is implicated in about 50% melanomas and 5% of colorectal cancers. In new results from 31 melanoma patients with the BRAF mutation who were treated with 960mg of PLX4032 twice a day, 64% (14) of the 22 patients who could be evaluated so far met the official criteria for partial response (this involves the diameter of tumours shrinking by at least 30% for at least a month). A further six of the 22 patients also showed a response, but, at the time of the congress presentation, it was too early to say whether the tumours would shrink far enough to meet these criteria.

Dr Paul Chapman, an attending physician on the Melanoma/Sarcoma service at Memorial Sloan-Kettering Cancer Center (New York, USA) and who was one of the leaders of the trial, told a news briefing: "We are very excited about these results. Of the 22 patients we have been able to evaluate so far, 20 have had some objective tumour shrinkage. This is impressive as they all had metastatic disease and most of them had failed several prior therapies. A lot of these patients were pretty sick but many of them had a significant and rapid improvement in the way they function. We've had patients come off oxygen and we've got several patients who have been able to come off narcotic pain medication soon after starting treatment."

The trial is investigating PLX4032 in patients with the BRAF mutation, and results from the first 55 patients were reported at
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
2. World-first swine-flu vaccine trial reveals one dose provides strong immune response
3. This idea doesnt stink: New tech cuts industrial odors, pollutants
4. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
5. Britains first swine-flu trials under way
6. Extraterrestrial platinum was stirred into the Earth
7. First genetically-engineered malaria vaccine to enter human trials
8. Results from trials of DHA in Alzheimers disease and age-related cognitive decline
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
11. Enzyme doesnt act alone in atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/30/2015)... 2015 To bolster its efforts and commitment to ... today the addition of two new team members. ... and David Raviv will act as head of ... commitment to providing the most secure solutions for the enterprise ... Layer 7 Technologies, a provider of security and management products, ...
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... What influence does the variation in estrogen level ... Using functional Magnetic Resonance Imaging, Jean-Claude Dreher, a ... 1), in collaboration with an American team from ... directed by Karen Berman, has identified, for the ...
... worldwide influenza pandemic caused by mutation of a bird-specific ... infectious avian strain has caused outbreaks of bird flu ... virus might also mutate to allow human-to-human transmission and ... protein, the polymerase, contribute to the ability of the ...
... by Dr. John Dick at Ontario Cancer Institute (OCI) have ... "human" leukemia stem cells. The converted cells, when transplanted ... can replicate the entire disease process from the very moment ... , Dr. Dick, Senior Scientist at OCI, the research ...
Cached Biology News:The influence of the menstrual cycle on the female brain 2The influence of the menstrual cycle on the female brain 3The influence of the menstrual cycle on the female brain 4A first glimpse of the influenza replication machine 2Cancer scientists create 'human' leukemia process to map how disease begins, progresses 2
(Date:7/2/2015)... , July 2, 2015  Spherix Incorporated (Nasdaq: ... fostering and monetization of intellectual property, today announced a ... Spherix Incorporated v. Verizon Services Corp. et al. , ... for the Eastern District of Virginia ... 1, 2015 interpreting certain key claims in favor of ...
(Date:7/1/2015)... ... July 01, 2015 , ... It is now possible to separate two ... photon emission computed tomography (SPECT) according to researchers from Amen Clinics, UCLA, Thomas ... brain scans and is believed to be the largest brain imaging study ever, will ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... ... July 01, 2015 , ... A newly launched business plan contest will ask ... to innovation in life sciences R&D. The Pistoia Alliance President’s Startup Challenge 2015 will ... and a period of expert mentorship from a senior industry figure drawn from the ...
Breaking Biology Technology:Spherix Issues A Litigation Update 2Spherix Issues A Litigation Update 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Pistoia Alliance Launches Startup Challenge 2Pistoia Alliance Launches Startup Challenge 3
... leader in providing automated, molecular testing solutions announced today ... Food and Drug Administration to market its INFINITI® CYP2C19 ... *17, of the CYP450 2C19 gene and is to ... the INFINITI® Analyzer.   "We are very ...
... (Nasdaq: OPTR ) is scheduled to present ... Hotel in New York City on Tuesday, November 2, ... http://photos.prnewswire.com/prnh/20090413/LA97352LOGO ) (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO ) ... be accessible on the Company,s website at www.optimerpharma.com ...
... DIEGO, Oct. 26 aTyr Pharma, the physiocrine ... C equity financing led by Domain Associates.  Domain ... and Polaris Ventures, who also participated in the ... development of aTyr,s preclinical pipeline and advance physiocrine ...
Cached Biology Technology:AutoGenomics Receives FDA Clearance for its INFINITI® CYP2C19 Assay 2Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference 2aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2
Anti-NCAPD3 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunoprecipitation, Western Blot...
...
...
BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
Biology Products: